<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529516</url>
  </required_header>
  <id_info>
    <org_study_id>109821</org_study_id>
    <nct_id>NCT00529516</nct_id>
  </id_info>
  <brief_title>Evaluate Safety &amp; Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults</brief_title>
  <official_title>Observer Blind Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals Influenza Vaccine GSK576389A Administered to Adults Over 65 Years Previously Vaccinated With the Same Vaccine, Compared to Fluarix™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Since influenza vaccines are administered every year because of the frequent change in their
      antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza
      vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this
      observer blind study, the subjects previously enrolled in study 104888 (NCT00377585) will
      receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only
      subjects who were previously enrolled in study 104888 (NCT00377585) are eligible for
      participation in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves 2 age groups (based on primary study):

      Subjects enrolled in the &gt;= 65 yrs age group in the primary study. Subjects enrolled in the
      18-40 yrs age group in the primary study. The study will be conducted in an open manner for
      this age group.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 15, 2007</start_date>
  <completion_date type="Actual">June 4, 2008</completion_date>
  <primary_completion_date type="Actual">December 21, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</measure>
    <time_frame>During a 7-day follow-up period after vaccination</time_frame>
    <description>Solicited local AEs assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited Local Adverse Events</measure>
    <time_frame>During a 7-day follow-up period after vaccination</time_frame>
    <description>Duration was expressed as the median number of days the symptom was experienced.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Adverse Events (AEs)</measure>
    <time_frame>During a 7-day follow-up period after vaccination</time_frame>
    <description>Solicited general AEs assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 40°C. Related: symptom assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited General Adverse Events</measure>
    <time_frame>During a 7-day follow-up period after vaccination</time_frame>
    <description>Duration was expressed as the median number of days the symptom was experienced.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During a 21-day follow-up period after vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: any AE regardless of intensity or relationship to vaccination. Grade 3: AE that prevented normal activity. Related: AE considered by the investigator to be causally related to the study vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>During the vaccination phase of the study (Day 0 to Day 20) and during the long term follow-up phase of the study (Day 21 to Day 179)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Medically Significant Conditions (MSCs)</measure>
    <time_frame>During the vaccination phase of the study (Day 0 to Day 20) and during the long term follow-up phase of the study (Day 21 to Day 179)</time_frame>
    <description>Medically significant conditions assessed include conditions prompting emergency room visits, hospitalizations or physician visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HI) Antibody Titers Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Titers were expressed as Geometric Mean Titers. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below1:10 and a post-vaccination titer greater than or equal to1:40 or a pre-vaccination titer greater than or equal to1:10 and at least a four-fold increase in post-vaccination titer. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factors for HI Antibodies Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Day 21</time_frame>
    <description>Seroconversion factor was defined as the fold increase in serum HI Geometric Mean Titers post-vaccination compared to Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to1:40 that is usually accepted as indicating protection. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cluster of Differentiation 4 (CD4) T-cells (Per Million CD4 T-cells) Producing at Least 2 Different Immune Markers</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of immune response marker-positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least CD40L and Another Immune Marker</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of CD40L-positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least IFN-γ and Another Immune Marker</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least IL-2 and Another Immune Marker</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least TNF-α and Another Immune Marker</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L) and interferon gamma (IFN-γ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cluster of Differentiation 8 (CD8) T-cells (Per Million CD8 T-cells) Expressing at Least 2 Different Immune Markers</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of immune response marker-positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least CD40L and Another Immune Marker</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of CD40L-positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least IFN-γ and Another Immune Marker</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least IL-2 and Another Immune Marker</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least TNF-α and Another Immune Marker</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L) and interferon gamma (IFN-γ).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1252</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>FluAS25 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix ≥ 65 years age Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix 18-40 years age Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>Fluarix 18-40 years age Group</arm_group_label>
    <arm_group_label>Fluarix ≥ 65 years age Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals Influenza Vaccine GSK576389A</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>FluAS25 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol should be enrolled in the study.

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by clinical
             evaluation before entering into the study.

          -  If the subject is female, she must be of non-childbearing potential or if she is of
             childbearing potential, she must practice adequate contraception for 30 days prior to
             vaccination, have a negative pregnancy test and continue such precautions for 2 months
             after completion of the vaccination series.

          -  Male or female subjects who participated in the 104888 study (NCT00377585) and were
             enrolled in the &gt;= 65 years age group or in the 18-40 years age group .

        Exclusion Criteria:

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study.

          -  Planned administration of a vaccine not foreseen by the study protocol up to 30 days
             after vaccination

          -  Planned administration of an influenza vaccine other than the study vaccines during
             the entire study period

          -  Any vaccination against influenza since January 2007

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required).

          -  History of hypersensitivity to a previous dose of influenza vaccine

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine(s)

          -  Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or pre-existing
             laboratory screening tests

          -  Acute disease at the time of enrolment

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days prior to vaccination, or planned use during the study
             period

          -  Any medical conditions in which IM injections are contraindicated

          -  Pregnant or lactating female, or planning to become pregnant or to discontinue
             contraceptive precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Messkirch</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88605</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haag</city>
        <state>Bayern</state>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoehenkirchen-Siegertsbrunn</city>
        <state>Bayern</state>
        <zip>85635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Langquaid</city>
        <state>Bayern</state>
        <zip>84085</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruedersdorf</city>
        <state>Brandenburg</state>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12687</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <zip>1319</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5094</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fredrikstad</city>
        <zip>N-1601</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haugesund</city>
        <zip>5507</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skien</city>
        <zip>3717</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>April 26, 2012</results_first_submitted>
  <results_first_submitted_qc>April 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2012</results_first_posted>
  <disposition_first_submitted>May 12, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 25, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluarix</keyword>
  <keyword>GSK Bio's influenza vaccine GSK576389A</keyword>
  <keyword>Influenza infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109821</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109821</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109821</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109821</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109821</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109821</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109821</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FluAS25 Group</title>
          <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
        </group>
        <group group_id="P2">
          <title>Fluarix ≥ 65 Years Age Group</title>
          <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
        </group>
        <group group_id="P3">
          <title>Fluarix 18-40 Years Age Group</title>
          <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
                <participants group_id="P2" count="488"/>
                <participants group_id="P3" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="472"/>
                <participants group_id="P2" count="486"/>
                <participants group_id="P3" count="288"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FluAS25 Group</title>
          <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
        </group>
        <group group_id="B2">
          <title>Fluarix ≥ 65 Years Age Group</title>
          <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
        </group>
        <group group_id="B3">
          <title>Fluarix 18-40 Years Age Group</title>
          <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="475"/>
            <count group_id="B2" value="488"/>
            <count group_id="B3" value="289"/>
            <count group_id="B4" value="1252"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.8" spread="5.50"/>
                    <measurement group_id="B2" value="73.7" spread="5.80"/>
                    <measurement group_id="B3" value="30.9" spread="6.64"/>
                    <measurement group_id="B4" value="63.86" spread="19.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="668"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
        <description>Solicited local AEs assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.</description>
        <time_frame>During a 7-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort on subjects who completed the symptom sheet.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
          <description>Solicited local AEs assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort on subjects who completed the symptom sheet.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited Local Adverse Events</title>
        <description>Duration was expressed as the median number of days the symptom was experienced.</description>
        <time_frame>During a 7-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects that reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local Adverse Events</title>
          <description>Duration was expressed as the median number of days the symptom was experienced.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects that reported the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N= 7; 7; 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="4.5" lower_limit="4.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N= 271; 76; 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N= 111; 14; 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N= 44; 8; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Adverse Events (AEs)</title>
        <description>Solicited general AEs assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 40°C. Related: symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 7-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort on subjects who completed the symptom sheet.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Adverse Events (AEs)</title>
          <description>Solicited general AEs assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 40°C. Related: symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort on subjects who completed the symptom sheet.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited General Adverse Events</title>
        <description>Duration was expressed as the median number of days the symptom was experienced.</description>
        <time_frame>During a 7-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects that experienced the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited General Adverse Events</title>
          <description>Duration was expressed as the median number of days the symptom was experienced.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects that experienced the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N= 80; 34; 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N= 131; 46; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N= 102; 49; 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N= 132; 51; 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N= 35; 23; 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N= 95; 31; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N= 17; 0; 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="NA">No Fever was experienced by any of the subjects in this arm.</measurement>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: any AE regardless of intensity or relationship to vaccination. Grade 3: AE that prevented normal activity. Related: AE considered by the investigator to be causally related to the study vaccination.</description>
        <time_frame>During a 21-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: any AE regardless of intensity or relationship to vaccination. Grade 3: AE that prevented normal activity. Related: AE considered by the investigator to be causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="488"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the vaccination phase of the study (Day 0 to Day 20) and during the long term follow-up phase of the study (Day 21 to Day 179)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="488"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs - Vaccination Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs - Vaccination Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs - Long Term Follow-up Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs - Long Term Follow-up Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Medically Significant Conditions (MSCs)</title>
        <description>Medically significant conditions assessed include conditions prompting emergency room visits, hospitalizations or physician visits.</description>
        <time_frame>During the vaccination phase of the study (Day 0 to Day 20) and during the long term follow-up phase of the study (Day 21 to Day 179)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Medically Significant Conditions (MSCs)</title>
          <description>Medically significant conditions assessed include conditions prompting emergency room visits, hospitalizations or physician visits.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="488"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MSCs - Vaccination Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 MSCs - Vaccination Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MSCs - Vaccination Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any MSCs - Long Term Follow-up Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="137"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 MSCs - Long Term Follow-up Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MSCs - Long Term Follow-up Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HI) Antibody Titers Against Each of the Three Vaccine Strains</title>
        <description>Titers were expressed as Geometric Mean Titers. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immunogenicity haemagglutination-inhibition (HI) which included all evaluable subjects who complied with the protocol up to the end of the active phase, for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HI) Antibody Titers Against Each of the Three Vaccine Strains</title>
          <description>Titers were expressed as Geometric Mean Titers. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immunogenicity haemagglutination-inhibition (HI) which included all evaluable subjects who complied with the protocol up to the end of the active phase, for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="461"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [Day 0] (N= 445; 461; 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="9.6" upper_limit="11.5"/>
                    <measurement group_id="O2" value="10.8" lower_limit="9.9" upper_limit="11.9"/>
                    <measurement group_id="O3" value="48.9" lower_limit="39.9" upper_limit="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [Day 21] (N= 447; 461; 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.5" lower_limit="92.4" upper_limit="115.8"/>
                    <measurement group_id="O2" value="53.7" lower_limit="47.6" upper_limit="60.7"/>
                    <measurement group_id="O3" value="143.4" lower_limit="125.8" upper_limit="163.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 0] (N= 445; 461; 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.0" lower_limit="97.7" upper_limit="123.9"/>
                    <measurement group_id="O2" value="79.5" lower_limit="70.5" upper_limit="89.7"/>
                    <measurement group_id="O3" value="112.5" lower_limit="98.1" upper_limit="129.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 21] (N= 447; 461; 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.6" lower_limit="394.0" upper_limit="470.6"/>
                    <measurement group_id="O2" value="217.9" lower_limit="196.3" upper_limit="241.8"/>
                    <measurement group_id="O3" value="251.2" lower_limit="226.4" upper_limit="278.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 0] (N= 445; 461; 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="86.8" upper_limit="105.7"/>
                    <measurement group_id="O2" value="82.5" lower_limit="75.2" upper_limit="90.6"/>
                    <measurement group_id="O3" value="110.5" lower_limit="95.9" upper_limit="127.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 21] (N= 447; 461; 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.2" lower_limit="187.1" upper_limit="218.5"/>
                    <measurement group_id="O2" value="152.3" lower_limit="140.0" upper_limit="165.6"/>
                    <measurement group_id="O3" value="209.2" lower_limit="188.9" upper_limit="231.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below1:10 and a post-vaccination titer greater than or equal to1:40 or a pre-vaccination titer greater than or equal to1:10 and at least a four-fold increase in post-vaccination titer. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immunogenicity haemagglutination-inhibition (HI) which included all evaluable subjects who complied with the protocol up to the end of the active phase, for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains</title>
          <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below1:10 and a post-vaccination titer greater than or equal to1:40 or a pre-vaccination titer greater than or equal to1:10 and at least a four-fold increase in post-vaccination titer. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immunogenicity haemagglutination-inhibition (HI) which included all evaluable subjects who complied with the protocol up to the end of the active phase, for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="461"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                    <measurement group_id="O2" value="238"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factors for HI Antibodies Against Each of the Three Vaccine Strains</title>
        <description>Seroconversion factor was defined as the fold increase in serum HI Geometric Mean Titers post-vaccination compared to Day 0.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immunogenicity haemagglutination-inhibition (HI) which included all evaluable subjects who complied with the protocol up to the end of the active phase, for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factors for HI Antibodies Against Each of the Three Vaccine Strains</title>
          <description>Seroconversion factor was defined as the fold increase in serum HI Geometric Mean Titers post-vaccination compared to Day 0.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immunogenicity haemagglutination-inhibition (HI) which included all evaluable subjects who complied with the protocol up to the end of the active phase, for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="461"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="8.7" upper_limit="11.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.4" upper_limit="5.5"/>
                    <measurement group_id="O3" value="2.9" lower_limit="2.5" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.5" upper_limit="4.3"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.5" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.2" lower_limit="2.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="2.0" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.7" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.7" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to1:40 that is usually accepted as indicating protection. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immunogenicity haemagglutination-inhibition (HI) which included all evaluable subjects who complied with the protocol up to the end of the active phase, for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to1:40 that is usually accepted as indicating protection. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for immunogenicity haemagglutination-inhibition (HI) which included all evaluable subjects who complied with the protocol up to the end of the active phase, for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="461"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [Day 0] (N= 445; 461; 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [Day 21] (N= 447; 461; 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381"/>
                    <measurement group_id="O2" value="306"/>
                    <measurement group_id="O3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 0] (N= 445; 461; 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381"/>
                    <measurement group_id="O2" value="362"/>
                    <measurement group_id="O3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 21] (N= 447; 461; 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445"/>
                    <measurement group_id="O2" value="442"/>
                    <measurement group_id="O3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 0] (N= 445; 461; 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="399"/>
                    <measurement group_id="O3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 21] (N= 447; 461; 271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445"/>
                    <measurement group_id="O2" value="443"/>
                    <measurement group_id="O3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cluster of Differentiation 4 (CD4) T-cells (Per Million CD4 T-cells) Producing at Least 2 Different Immune Markers</title>
        <description>Results are presented as the geometric mean number of immune response marker-positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cluster of Differentiation 4 (CD4) T-cells (Per Million CD4 T-cells) Producing at Least 2 Different Immune Markers</title>
          <description>Results are presented as the geometric mean number of immune response marker-positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 62; 60; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830.72" spread="889.90"/>
                    <measurement group_id="O2" value="674.91" spread="567.07"/>
                    <measurement group_id="O3" value="1276.25" spread="701.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 65; 63; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2013.28" spread="1388.55"/>
                    <measurement group_id="O2" value="1010.22" spread="1069.96"/>
                    <measurement group_id="O3" value="1607.66" spread="839.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least CD40L and Another Immune Marker</title>
        <description>Results are presented as the geometric mean number of CD40L-positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least CD40L and Another Immune Marker</title>
          <description>Results are presented as the geometric mean number of CD40L-positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 62; 60; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="822.37" spread="875.39"/>
                    <measurement group_id="O2" value="660.01" spread="560.95"/>
                    <measurement group_id="O3" value="1260.65" spread="681.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 65; 63; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1961.18" spread="1337.11"/>
                    <measurement group_id="O2" value="981.82" spread="1056.18"/>
                    <measurement group_id="O3" value="1556.00" spread="830.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least IFN-γ and Another Immune Marker</title>
        <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least IFN-γ and Another Immune Marker</title>
          <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 62; 60; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513.25" spread="586.78"/>
                    <measurement group_id="O2" value="371.64" spread="397.45"/>
                    <measurement group_id="O3" value="753.45" spread="556.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 65; 63; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1081.11" spread="966.36"/>
                    <measurement group_id="O2" value="574.28" spread="685.03"/>
                    <measurement group_id="O3" value="870.84" spread="589.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least IL-2 and Another Immune Marker</title>
        <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least IL-2 and Another Immune Marker</title>
          <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 62; 60; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="769.96" spread="809.58"/>
                    <measurement group_id="O2" value="634.57" spread="518.17"/>
                    <measurement group_id="O3" value="1030.23" spread="585.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 65; 63; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1644.34" spread="1110.14"/>
                    <measurement group_id="O2" value="856.60" spread="855.82"/>
                    <measurement group_id="O3" value="1288.54" spread="664.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least TNF-α and Another Immune Marker</title>
        <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L) and interferon gamma (IFN-γ).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least TNF-α and Another Immune Marker</title>
          <description>Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L) and interferon gamma (IFN-γ).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD4 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 62; 60; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586.39" spread="698.83"/>
                    <measurement group_id="O2" value="409.05" spread="415.62"/>
                    <measurement group_id="O3" value="746.02" spread="551.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 65; 63; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1189.34" spread="945.05"/>
                    <measurement group_id="O2" value="608.51" spread="700.32"/>
                    <measurement group_id="O3" value="921.15" spread="549.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cluster of Differentiation 8 (CD8) T-cells (Per Million CD8 T-cells) Expressing at Least 2 Different Immune Markers</title>
        <description>Results are presented as the geometric mean number of immune response marker-positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cluster of Differentiation 8 (CD8) T-cells (Per Million CD8 T-cells) Expressing at Least 2 Different Immune Markers</title>
          <description>Results are presented as the geometric mean number of immune response marker-positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 55; 54; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="166.35"/>
                    <measurement group_id="O2" value="6.82" spread="123.10"/>
                    <measurement group_id="O3" value="3.56" spread="247.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 64; 62; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.75" spread="168.54"/>
                    <measurement group_id="O2" value="6.51" spread="112.42"/>
                    <measurement group_id="O3" value="3.48" spread="79.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least CD40L and Another Immune Marker</title>
        <description>Results are presented as the geometric mean number of CD40L-positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least CD40L and Another Immune Marker</title>
          <description>Results are presented as the geometric mean number of CD40L-positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 55; 54; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="120.88"/>
                    <measurement group_id="O2" value="4.33" spread="134.18"/>
                    <measurement group_id="O3" value="2.12" spread="220.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 64; 62; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.09" spread="123.89"/>
                    <measurement group_id="O2" value="5.79" spread="85.20"/>
                    <measurement group_id="O3" value="3.64" spread="71.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least IFN-γ and Another Immune Marker</title>
        <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least IFN-γ and Another Immune Marker</title>
          <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 55; 54; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="69.92"/>
                    <measurement group_id="O2" value="2.64" spread="50.62"/>
                    <measurement group_id="O3" value="1.58" spread="32.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 64; 62; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="97.36"/>
                    <measurement group_id="O2" value="2.82" spread="56.06"/>
                    <measurement group_id="O3" value="2.17" spread="28.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least IL-2 and Another Immune Marker</title>
        <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least IL-2 and Another Immune Marker</title>
          <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 55; 54; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="135.79"/>
                    <measurement group_id="O2" value="8.43" spread="119.70"/>
                    <measurement group_id="O3" value="3.21" spread="249.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 64; 62; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.70" spread="159.08"/>
                    <measurement group_id="O2" value="5.64" spread="101.15"/>
                    <measurement group_id="O3" value="3.20" spread="55.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least TNF-α and Another Immune Marker</title>
        <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L) and interferon gamma (IFN-γ).</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥ 65 Years Age Group</title>
            <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 18-40 Years Age Group</title>
            <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least TNF-α and Another Immune Marker</title>
          <description>Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L) and interferon gamma (IFN-γ).</description>
          <population>The analysis was performed on the ATP cohort of immunogenicity Cell-Mediated Immunity (CMI) which included a subset of subjects from the ATP Cohort for immunogenicity HI. This included subjects for whom data for immune response marker-positive CD8 result was available 21 days after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 55; 54; 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="72.38"/>
                    <measurement group_id="O2" value="2.48" spread="42.55"/>
                    <measurement group_id="O3" value="3.13" spread="44.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (N= 64; 62; 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67" spread="89.23"/>
                    <measurement group_id="O2" value="3.54" spread="69.71"/>
                    <measurement group_id="O3" value="2.73" spread="40.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events collected by systematic assessment: 7-day follow-up period after vaccination. Events collected by non-systematic method are reported during the active phase (Day 0 - 20) and during the long term follow-up phase (Day 21 - 179) of the study.</time_frame>
      <desc>Events collected by systematic assessment are reported for subjects with a symptom diary card available. Events collected by non-systematic method are reported for the Total Vaccinated Cohort.</desc>
      <group_list>
        <group group_id="E1">
          <title>FluAS25 Group</title>
          <description>Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.</description>
        </group>
        <group group_id="E2">
          <title>Fluarix ≥ 65 Years Age Group</title>
          <description>Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
        </group>
        <group group_id="E3">
          <title>Fluarix 18-40 Years Age Group</title>
          <description>Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Reported during the active phase of the study (Day 0 - 20)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>Reported during the active phase of the study (Day 0 - 20)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <description>Reported during the active phase of the study (Day 0 - 20)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <description>Reported during the active phase of the study (Day 0 - 20)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <description>Reported during the active phase of the study (Day 0 - 20)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <description>Reported during the active phase of the study (Day 0 - 20)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Precursor b-lymphoblastic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="271" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="170" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="271" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="170" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

